

Jeffrey E Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11202090/publications.pdf>

Version: 2024-02-01

308
papers

29,973
citations

4345

89
h-index

6686

161
g-index

313
all docs

313
docs citations

313
times ranked

26581
citing authors

#	ARTICLE	IF	CITATIONS
1	B cells and tertiary lymphoid structures promote immunotherapy response. <i>Nature</i> , 2020, 577, 549-555.	13.7	1,421
2	Multi-Institutional Melanoma Lymphatic Mapping Experience: The Prognostic Value of Sentinel Lymph Node Status in 612 Stage I or II Melanoma Patients. <i>Journal of Clinical Oncology</i> , 1999, 17, 976-976.	0.8	1,166
3	Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy. <i>Annals of Surgical Oncology</i> , 2006, 13, 1035-1046.	0.7	803
4	Borderline Resectable Pancreatic Cancer: The Importance of This Emerging Stage of Disease. <i>Journal of the American College of Surgeons</i> , 2008, 206, 833-846.	0.2	740
5	Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head. <i>Journal of Clinical Oncology</i> , 2008, 26, 3496-3502.	0.8	684
6	Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. <i>Nature Medicine</i> , 2018, 24, 1649-1654.	15.2	592
7	Impact of Resection Status on Pattern of Failure and Survival After Pancreaticoduodenectomy for Pancreatic Adenocarcinoma. <i>Annals of Surgery</i> , 2007, 246, 52-60.	2.1	508
8	Pancreaticoduodenectomy with vascular resection: margin status and survival duration. <i>Journal of Gastrointestinal Surgery</i> , 2004, 8, 935-950.	0.9	502
9	Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. <i>Lancet Oncology</i> , 2018, 19, 310-322.	5.1	486
10	Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. <i>Surgery</i> , 2003, 134, 946-954.	1.0	480
11	Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. <i>Cancer</i> , 2012, 118, 5749-5756.	2.0	457
12	Preoperative Gemcitabine and Cisplatin Followed by Gemcitabine-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic Head. <i>Journal of Clinical Oncology</i> , 2008, 26, 3487-3495.	0.8	441
13	Long-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2009, 16, 836-47.	0.7	435
14	Improved preoperative planning for directed parathyroidectomy with 4-dimensional computed tomography. <i>Surgery</i> , 2006, 140, 932-941.	1.0	383
15	Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases. <i>JAMA Oncology</i> , 2017, 3, 636.	3.4	376
16	Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients. <i>Clinical Cancer Research</i> , 2012, 18, 6758-6770.	3.2	345
17	Prospective, Randomized Trial of Octreotide to Prevent Pancreatic Fistula After Pancreaticoduodenectomy for Malignant Disease. <i>Annals of Surgery</i> , 1997, 226, 632-641.	2.1	339
18	Rationale for En Bloc Vein Resection in the Treatment of Pancreatic Adenocarcinoma Adherent to the Superior Mesenteric-Portal Vein Confluence. <i>Annals of Surgery</i> , 1996, 223, 154-162.	2.1	327

#	ARTICLE	IF	CITATIONS
19	Neoadjuvant Chemoradiotherapy for Adenocarcinoma of the Pancreas: Treatment Variables and Survival Duration. <i>Annals of Surgical Oncology</i> , 2001, 8, 123-132.	0.7	326
20	Contemporary Diagnostic Imaging Modalities for the Staging and Surveillance of Melanoma Patients: a Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2011, 103, 129-142.	3.0	297
21	Adrenal cortical carcinoma. <i>World Journal of Surgery</i> , 2001, 25, 914-926.	0.8	295
22	Ethnic Differences Among Patients With Cutaneous Melanoma. <i>Archives of Internal Medicine</i> , 2006, 166, 1907.	4.3	292
23	RET Proto-Oncogene: A Review and Update of Genotype-Phenotype Correlations in Hereditary Medullary Thyroid Cancer and Associated Endocrine Tumors. <i>Thyroid</i> , 2005, 15, 531-544.	2.4	269
24	Effect of Preoperative Biliary Decompression on Pancreaticoduodenectomy-Associated Morbidity in 300 Consecutive Patients. <i>Annals of Surgery</i> , 2001, 234, 47-55.	2.1	267
25	Diagnostic Accuracy of Endoscopic Ultrasound-Guided Fine-Needle Aspiration in Patients With Presumed Pancreatic Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2003, 7, 118-128.	0.9	248
26	Nonfunctioning islet cell carcinoma of the pancreas: Survival results in a contemporary series of 163 patients. <i>Surgery</i> , 2001, 130, 1078-1085.	1.0	243
27	Fine-needle aspiration of the thyroid and correlation with histopathology in a contemporary series of 240 patients. <i>American Journal of Surgery</i> , 2003, 186, 702-710.	0.9	239
28	Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , 2018, 19, 181-193.	5.1	233
29	Genome-wide association study identifies three new melanoma susceptibility loci. <i>Nature Genetics</i> , 2011, 43, 1108-1113.	9.4	230
30	Role for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Thick (≥ 4 mm) Primary Melanoma. <i>Annals of Surgical Oncology</i> , 2000, 7, 160-165.	0.7	225
31	Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. <i>American Journal of Surgery</i> , 1996, 171, 118-125.	0.9	220
32	Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma. <i>Nature Genetics</i> , 2015, 47, 987-995.	9.4	218
33	Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma. <i>Cancer</i> , 2012, 118, 3182-3190.	2.0	216
34	Laparoscopic resection of adrenal cortical carcinoma: A cautionary note. <i>Surgery</i> , 2005, 138, 1078-1086.	1.0	212
35	Phase I Trial Evaluating the Safety of Bevacizumab With Concurrent Radiotherapy and Capecitabine in Locally Advanced Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 1145-1151.	0.8	203
36	Multiple Endocrine Neoplasia Type 2. <i>Archives of Surgery</i> , 2003, 138, 409.	2.3	196

#	ARTICLE	IF	CITATIONS
37	Surgical margins and prognostic factors in patients with thick (>4 mm) primary melanoma. <i>Annals of Surgical Oncology</i> , 1998, 5, 322-328.	0.7	192
38	Predictors and Natural History of In-Transit Melanoma After Sentinel Lymphadenectomy. <i>Annals of Surgical Oncology</i> , 2005, 12, 587-596.	0.7	192
39	Microscopic Tumor Burden in Sentinel Lymph Nodes Predicts Synchronous Nonsentinel Lymph Node Involvement in Patients With Melanoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 4296-4303.	0.8	190
40	Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. <i>Surgery</i> , 1998, 124, 203-210.	1.0	188
41	Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. <i>Human Molecular Genetics</i> , 2011, 20, 5012-5023.	1.4	187
42	Revised American Joint Committee on Cancer Staging Criteria Accurately Predict Sentinel Lymph Node Positivity in Clinically Node-Negative Melanoma Patients. <i>Annals of Surgical Oncology</i> , 2003, 10, 569-574.	0.7	186
43	Parathyroid Exploration in the Reoperative Neck: Improved Preoperative Localization with 4D-Computed Tomography. <i>Journal of the American College of Surgeons</i> , 2008, 206, 888-895.	0.2	184
44	Preoperative Paclitaxel and Concurrent Rapid-Fractionation Radiation for Resectable Pancreatic Adenocarcinoma: Toxicities, Histologic Response Rates, and Event-Free Outcome. <i>Journal of Clinical Oncology</i> , 2002, 20, 2537-2544.	0.8	180
45	Cost and Utilization Impact of a Clinical Pathway for Patients Undergoing Pancreaticoduodenectomy. <i>Annals of Surgical Oncology</i> , 2000, 7, 484-489.	0.7	178
46	Cortical-sparing adrenalectomy for patients with bilateral pheochromocytoma. <i>Surgery</i> , 1996, 120, 1064-1071.	1.0	174
47	Invasive Squamous Cell Carcinoma of the Skin: Defining a High-Risk Group. <i>Annals of Surgical Oncology</i> , 2006, 13, 902-909.	0.7	173
48	Treatment Sequencing for Resectable Pancreatic Cancer: Influence of Early Metastases and Surgical Complications on Multimodality Therapy Completion and Survival. <i>Journal of Gastrointestinal Surgery</i> , 2014, 18, 16-25.	0.9	172
49	Perineural and Intra-neural Invasion in Posttherapy Pancreaticoduodenectomy Specimens Predicts Poor Prognosis in Patients With Pancreatic Ductal Adenocarcinoma. <i>American Journal of Surgical Pathology</i> , 2012, 36, 409-417.	2.1	158
50	The learning curve in pancreatic surgery. <i>Surgery</i> , 2007, 141, 694-701.	1.0	157
51	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , The, 2019, 20, e378-e389.	5.1	155
52	Management of Pancreatic Endocrine Tumors in Multiple Endocrine Neoplasia Type 1. <i>World Journal of Surgery</i> , 2006, 30, 643-653.	0.8	151
53	Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. <i>Hpb</i> , 2014, 16, 430-438.	0.1	151
54	Repair of UV Light-Induced DNA Damage and Risk of Cutaneous Malignant Melanoma. <i>Journal of the National Cancer Institute</i> , 2003, 95, 308-315.	3.0	149

#	ARTICLE	IF	CITATIONS
55	Evaluation and surgical resection of adrenal masses in patients with a history of extra-adrenal malignancy. <i>Surgery</i> , 2001, 130, 1060-1067.	1.0	142
56	Sphincter-Sparing Local Excision and Adjuvant Radiation for Anal-Rectal Melanoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 4555-4558.	0.8	140
57	Recurrence of Adrenal Cortical Carcinoma Following Resection: Surgery Alone Can Achieve Results Equal to Surgery Plus Mitotane. <i>Annals of Surgical Oncology</i> , 2010, 17, 263-270.	0.7	140
58	Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3. <i>Nature Genetics</i> , 2011, 43, 1114-1118.	9.4	140
59	Prospective Assessment of Postoperative Complications and Associated Costs Following Inguinal Lymph Node Dissection (ILND) in Melanoma Patients. <i>Annals of Surgical Oncology</i> , 2010, 17, 2764-2772.	0.7	139
60	Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. <i>Nature Genetics</i> , 2020, 52, 494-504.	9.4	138
61	Intraductal Papillary Mucinous Neoplasms of the Pancreas: Effect of Invasion and Pancreatic Margin Status on Recurrence and Survival. <i>Annals of Surgical Oncology</i> , 2006, 13, 582-594.	0.7	130
62	Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation. <i>Annals of Surgical Oncology</i> , 2010, 17, 1794-1801.	0.7	129
63	Surgical Strategy for the Treatment of Medullary Thyroid Carcinoma. <i>Annals of Surgery</i> , 1999, 230, 697.	2.1	129
64	Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 2416-2423.	0.7	125
65	Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 164-174.	0.9	124
66	Assessment of the role of sentinel lymph node biopsy for primary cutaneous desmoplastic melanoma. <i>Cancer</i> , 2006, 106, 900-906.	2.0	122
67	Surgical management of hereditary pheochromocytoma ¹ 1No competing interests declared.. <i>Journal of the American College of Surgeons</i> , 2004, 198, 525-534.	0.2	120
68	Delayed Recovery after Pancreaticoduodenectomy: A Major Factor Impairing the Delivery of Adjuvant Therapy?. <i>Journal of the American College of Surgeons</i> , 2007, 204, 347-355.	0.2	119
69	Ninety-day Postoperative Mortality Is a Legitimate Measure of Hepatopancreatobiliary Surgical Quality. <i>Annals of Surgery</i> , 2015, 262, 1071-1078.	2.1	115
70	Unknown primary cancer presenting as an adrenal mass: Frequency and implications for diagnostic evaluation of adrenal incidentalomas. <i>Surgery</i> , 1998, 124, 1115-1122.	1.0	114
71	Genotype-Phenotype Analysis in Multiple Endocrine Neoplasia Type 1. <i>Archives of Surgery</i> , 2002, 137, 641.	2.3	112
72	Pancreaticoduodenectomy After Placement of Endobiliary Metal Stents. <i>Journal of Gastrointestinal Surgery</i> , 2005, 9, 1094-1105.	0.9	112

#	ARTICLE	IF	CITATIONS
73	Surgical management, DNA content, and patient survival in adrenal cortical carcinoma. <i>Surgery</i> , 1995, 118, 1090-1098.	1.0	111
74	A variant in FTO shows association with melanoma risk not due to BMI. <i>Nature Genetics</i> , 2013, 45, 428-432.	9.4	111
75	Adjuvant irradiation for axillary metastases from malignant melanoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 964-972.	0.4	110
76	Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. <i>Annals of Diagnostic Pathology</i> , 2012, 16, 29-37.	0.6	110
77	The Need for Standardized Pathologic Staging of Pancreaticoduodenectomy Specimens. <i>Pancreas</i> , 1996, 12, 373-380.	0.5	109
78	Selective Reoperation for Locally Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma Following Primary Pancreatic Resection. <i>Journal of Gastrointestinal Surgery</i> , 2012, 16, 1696-1704.	0.9	109
79	The Effect on Melanoma Risk of Genes Previously Associated With Telomere Length. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	109
80	Optimal treatment strategy in patients with papillary thyroid cancer: A decision analysis. <i>Surgery</i> , 2001, 130, 921-930.	1.0	108
81	Neoadjuvant Therapy is Associated with a Reduced Lymph Node Ratio in Patients with Potentially Resectable Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 1168-1175.	0.7	108
82	Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. <i>JAMA Surgery</i> , 2020, 155, 832.	2.2	105
83	Genome-wide association studies identify several new loci associated with pigmentation traits and skin cancer risk in European Americans. <i>Human Molecular Genetics</i> , 2013, 22, 2948-2959.	1.4	104
84	Radiographic Tumor-Vein Interface as a Predictor of Intraoperative, Pathologic, and Oncologic Outcomes in Resectable and Borderline Resectable Pancreatic Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2014, 18, 269-278.	0.9	102
85	Does laparoscopic adrenalectomy jeopardize oncologic outcomes for patients with adrenocortical carcinoma?. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2013, 27, 4026-4032.	1.3	101
86	Effect of Neoadjuvant Chemoradiation and Surgical Technique on Recurrence of Localized Pancreatic Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2012, 16, 68-79.	0.9	98
87	Defined Clinical Classifications Are Associated with Outcome of Patients with Anatomically Resectable Pancreatic Adenocarcinoma Treated with Neoadjuvant Therapy. <i>Annals of Surgical Oncology</i> , 2012, 19, 2045-2053.	0.7	96
88	Posterior retroperitoneoscopic adrenalectomy is a safe and effective alternative to transabdominal laparoscopic adrenalectomy for pheochromocytoma. <i>Surgery</i> , 2011, 150, 452-458.	1.0	94
89	Biochemotherapy in patients with metastatic anorectal mucosal melanoma. <i>Cancer</i> , 2004, 100, 1478-1483.	2.0	92
90	Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma. <i>Cancer</i> , 2006, 107, 2647-2652.	2.0	92

#	ARTICLE	IF	CITATIONS
91	Genome-wide association study identifies novel alleles associated with risk of cutaneous basal cell carcinoma and squamous cell carcinoma. <i>Human Molecular Genetics</i> , 2011, 20, 3718-3724.	1.4	92
92	HLA-DQB1*0301 association with increased cutaneous melanoma risk. <i>International Journal of Cancer</i> , 1994, 59, 510-513.	2.3	91
93	Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival. <i>American Journal of Surgical Pathology</i> , 2016, 40, 1653-1660.	2.1	91
94	Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. <i>Clinical Cancer Research</i> , 2018, 24, 4416-4428.	3.2	89
95	The learning curve in pancreatic surgery. <i>Surgery</i> , 2007, 141, 456-463.	1.0	88
96	Managing unsuspected tumor invasion of the superior mesenteric-portal venous confluence during pancreaticoduodenectomy. <i>American Journal of Surgery</i> , 1994, 168, 352-354.	0.9	87
97	Implications of lymphatic drainage to unusual sentinel lymph node sites in patients with primary cutaneous melanoma. <i>Cancer</i> , 2002, 95, 354-360.	2.0	87
98	Risk of venous thromboembolism outweighs post-hepatectomy bleeding complications: analysis of 5651 National Surgical Quality Improvement Program patients. <i>Hpb</i> , 2012, 14, 506-513.	0.1	87
99	Significance of peritoneal cytology in patients with potentially resectable adenocarcinoma of the pancreatic head. <i>Surgery</i> , 1995, 118, 472-478.	1.0	86
100	Population-Based Assessment of Surgical Treatment Trends for Patients With Melanoma in the Era of Sentinel Lymph Node Biopsy. <i>Journal of Clinical Oncology</i> , 2005, 23, 6054-6062.	0.8	86
101	Utility of Computed Tomography and Magnetic Resonance Imaging Staging Before Completion Lymphadenectomy in Patients With Sentinel Lymph Node-Positive Melanoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 2858-2865.	0.8	86
102	A Retrospective Cohort Analysis of the Efficacy of Adjuvant Radiotherapy after Primary Surgical Resection in Patients with Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 192-197.	1.8	86
103	Failure to Recognize Multiple Endocrine Neoplasia 2B: More Common Than We Think?. <i>Annals of Surgical Oncology</i> , 2008, 15, 293-301.	0.7	85
104	Limitations of size as a criterion in the evaluation of adrenal tumors. <i>Surgery</i> , 2000, 128, 973-983.	1.0	84
105	PGC-1 Coactivators Regulate MITF and the Tanning Response. <i>Molecular Cell</i> , 2013, 49, 145-157.	4.5	84
106	Long-Term Outcomes of Surgical Treatment for Hereditary Pheochromocytoma. <i>Journal of the American College of Surgeons</i> , 2013, 216, 280-289.	0.2	84
107	Anatomy of the Superior Mesenteric Vein With Special Reference to the Surgical Management of First-order Branch Involvement at Pancreaticoduodenectomy. <i>Annals of Surgery</i> , 2008, 248, 1098-1102.	2.1	83
108	Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. <i>JAMA Surgery</i> , 2017, 152, 1048.	2.2	82

#	ARTICLE	IF	CITATIONS
109	Posttherapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. <i>Cancer</i> , 2012, 118, 268-277.	2.0	81
110	Significance of Multiple Nodal Basin Drainage in Truncal Melanoma Patients Undergoing Sentinel Lymph Node Biopsy. <i>Annals of Surgical Oncology</i> , 2000, 7, 256-261.	0.7	80
111	Polymorphisms in the DNA Repair Genes XPC, XPD, and XPG and Risk of Cutaneous Melanoma: a Case-Control Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 2526-2532.	1.1	80
112	Posterior Retroperitoneoscopic Adrenalectomy. <i>Annals of Surgery</i> , 2008, 248, 666-674.	2.1	80
113	Combined-modality therapy for patients with regional nodal metastases from melanoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 106-113.	0.4	78
114	Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients. <i>Surgery</i> , 2003, 134, 890-899.	1.0	77
115	Genetic variants of the ADPRT, XRCC1 and APE1 genes and risk of cutaneous melanoma. <i>Carcinogenesis</i> , 2006, 27, 1894-1901.	1.3	77
116	Prospective assessment of the reliability, validity, and sensitivity to change of the functional assessment of cancer Therapy-Melanoma questionnaire. <i>Cancer</i> , 2008, 112, 2249-2257.	2.0	77
117	Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy. <i>Hpb</i> , 2012, 14, 365-372.	0.1	77
118	Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma. <i>Surgery</i> , 2007, 142, 867-875.	1.0	76
119	A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 5883-5894.	3.2	76
120	Preoperative Chemoradiation for Patients With Pancreatic Cancer: Toxicity of Endobiliary Stents. <i>Journal of Clinical Oncology</i> , 2000, 18, 860-860.	0.8	75
121	Venous resection in pancreatic cancer surgery. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2006, 20, 349-364.	1.0	75
122	Conditional survival estimates improve over time for patients with advanced melanoma. <i>Cancer</i> , 2010, 116, 2234-2241.	2.0	74
123	Home-Based Exercise Prehabilitation During Preoperative Treatment for Pancreatic Cancer Is Associated With Improvement in Physical Function and Quality of Life. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541989406.	0.8	72
124	Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck. <i>Cancer</i> , 2004, 100, 383-389.	2.0	71
125	Pheochromocytoma: Advances in Genetics, Diagnosis, Localization, and Treatment. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 509-525.	0.9	71
126	C-Reactive Protein As a Marker of Melanoma Progression. <i>Journal of Clinical Oncology</i> , 2015, 33, 1389-1396.	0.8	71

#	ARTICLE	IF	CITATIONS
127	Melanoma adrenal metastasis: natural history and surgical management. <i>American Journal of Surgery</i> , 2008, 195, 363-369.	0.9	69
128	A Critical Assessment of Adjuvant Radiotherapy for Inguinal Lymph Node Metastases from Melanoma. <i>Annals of Surgical Oncology</i> , 2004, 11, 1079-1084.	0.7	66
129	RET Fusion as a Novel Driver of Medullary Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 788-793.	1.8	65
130	Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein. <i>Journal of Clinical Oncology</i> , 2016, 34, 1741-1747.	0.8	64
131	Surgical treatment of non-functioning pancreatic islet cell tumors. <i>Journal of Surgical Oncology</i> , 2005, 89, 170-185.	0.8	63
132	Screening for MEN1 mutations in patients with atypical endocrine neoplasia. <i>Surgery</i> , 1999, 126, 1097-1104.	1.0	62
133	Prognostic Significance of New AJCC Tumor Stage in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Therapy. <i>American Journal of Surgical Pathology</i> , 2017, 41, 1097-1104.	2.1	62
134	Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. <i>Cancer</i> , 2012, 118, 3801-3811.	2.0	61
135	Frequency and Intensity of Postoperative Surveillance After Curative Treatment of Pancreatic Cancer: A Cost-Effectiveness Analysis. <i>Annals of Surgical Oncology</i> , 2013, 20, 2197-2203.	0.7	61
136	The Cost-Effectiveness of Neoadjuvant Chemoradiation is Superior to a Surgery-First Approach in the Treatment of Pancreatic Head Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2013, 20, 500-508.	0.7	61
137	Two-stage genome-wide association study identifies a novel susceptibility locus associated with melanoma. <i>Oncotarget</i> , 2017, 8, 17586-17592.	0.8	61
138	Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. <i>Annals of Surgery</i> , 2021, 273, 806-813.	2.1	61
139	Posterior Retroperitoneoscopic Adrenalectomy: A Contemporary American Experience. <i>Journal of the American College of Surgeons</i> , 2011, 212, 659-665.	0.2	59
140	Retroperitoneal Dissection in Patients with Borderline Resectable Pancreatic Cancer: Operative Principles and Techniques. <i>Journal of the American College of Surgeons</i> , 2012, 215, e11-e18.	0.2	59
141	Haplotype and genotypes of the <i>VDR</i> gene and cutaneous melanoma risk in non-Hispanic whites in Texas: A case-control study. <i>International Journal of Cancer</i> , 2008, 122, 2077-2084.	2.3	58
142	Superior Mesenteric Artery Margin of Posttherapy Pancreaticoduodenectomy and Prognosis in Patients With Pancreatic Ductal Adenocarcinoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1395-1403.	2.1	58
143	Active Surveillance for Adverse Events Within 90 Days: The Standard for Reporting Surgical Outcomes After Pancreatectomy. <i>Annals of Surgical Oncology</i> , 2015, 22, 3522-3529.	0.7	58
144	Pelvic Lymph Node Dissection Is Beneficial in Subsets of Patients with Node-positive Melanoma. <i>Annals of Surgical Oncology</i> , 2007, 14, 2867-2875.	0.7	56

#	ARTICLE	IF	CITATIONS
145	Chemotherapy Versus Chemoradiation as Preoperative Therapy for Resectable Pancreatic Ductal Adenocarcinoma. <i>Pancreas</i> , 2019, 48, 216-222.	0.5	56
146	Fibrin sealant does not decrease seroma output or time to drain removal following inguino-femoral lymph node dissection in melanoma patients: A randomized controlled trial (NCT00506311). <i>World Journal of Surgical Oncology</i> , 2008, 6, 63.	0.8	55
147	PET/CT in the Management of Patients With Stage IIIC and IV Metastatic Melanoma Considered Candidates for Surgery: Evaluation of the Additive Value After Conventional Imaging. <i>American Journal of Roentgenology</i> , 2012, 198, 902-908.	1.0	54
148	Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. <i>Nature</i> , 2022, 606, 797-803.	13.7	54
149	Tumor Invasion of Muscular Vessels Predicts Poor Prognosis in Patients With Pancreatic Ductal Adenocarcinoma Who Have Received Neoadjuvant Therapy and Pancreaticoduodenectomy. <i>American Journal of Surgical Pathology</i> , 2012, 36, 552-559.	2.1	53
150	In Vitro Sensitivity to Ultraviolet B Light and Skin Cancer Risk: A Case-Control Analysis. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1822-1831.	3.0	52
151	Borderline Resectable Adrenal Cortical Carcinoma: A Potential Role for Preoperative Chemotherapy. <i>World Journal of Surgery</i> , 2014, 38, 1318-1327.	0.8	52
152	Home-based exercise during preoperative therapy for pancreatic cancer. <i>Langenbeck's Archives of Surgery</i> , 2017, 402, 1175-1185.	0.8	52
153	How many lymph nodes are enough during sentinel lymphadenectomy for primary melanoma?. <i>Surgery</i> , 2000, 128, 306-311.	1.0	51
154	Morbidity and Mortality after Pancreaticoduodenectomy in Patients with Borderline Resectable Type C Clinical Classification. <i>Journal of Gastrointestinal Surgery</i> , 2014, 18, 146-156.	0.9	51
155	The surgical treatment of medullary thyroid carcinoma. , 1999, 16, 50-63.		50
156	Genetic Variants of the Vitamin D Receptor Gene Alter Risk of Cutaneous Melanoma. <i>Journal of Investigative Dermatology</i> , 2007, 127, 276-280.	0.3	50
157	Regional Nodal basin control is not compromised by previous sentinel lymph node biopsy in patients with melanoma. <i>Annals of Surgical Oncology</i> , 2000, 7, 226-231.	0.7	49
158	Genetic variants and haplotypes of the caspase-8 and caspase-10 genes contribute to susceptibility to cutaneous melanoma. <i>Human Mutation</i> , 2008, 29, 1443-1451.	1.1	49
159	Fear of Cancer Recurrence after Curative Pancreatectomy: A Cross-sectional Study in Survivors of Pancreatic and Periampullary Tumors. <i>Annals of Surgical Oncology</i> , 2012, 19, 4078-4084.	0.7	49
160	Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. <i>Cancer</i> , 2016, 122, 2671-2679.	2.0	49
161	Impact of Clinical and Pathologic Features on Tumor-Infiltrating Lymphocyte Expansion from Surgically Excised Melanoma Metastases for Adoptive T-cell Therapy. <i>Clinical Cancer Research</i> , 2011, 17, 4882-4891.	3.2	48
162	Variability in melanoma post-treatment surveillance practices by country and physician specialty. <i>Melanoma Research</i> , 2012, 22, 376-385.	0.6	48

#	ARTICLE	IF	CITATIONS
163	Clinical Calculator of Conditional Survival Estimates for Resected and Unresected Survivors of Pancreatic Cancer. <i>Archives of Surgery</i> , 2012, 147, 513-9.	2.3	48
164	Genetic variants in Hippo pathway genes <i>YAP1</i> , <i>TEAD1</i> and <i>TEAD4</i> are associated with melanoma-specific survival. <i>International Journal of Cancer</i> , 2015, 137, 638-645.	2.3	48
165	Adrenal Medullary Disease in Multiple Endocrine Neoplasia Type 2: Appropriate Management. <i>Endocrinology and Metabolism Clinics of North America</i> , 1994, 23, 167-176.	1.2	48
166	Posterior Retroperitoneoscopic Adrenalectomy. <i>Advances in Surgery</i> , 2009, 43, 147-157.	0.6	47
167	Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy. <i>Pancreas</i> , 2017, 46, 1180-1187.	0.5	47
168	Is Surveillance Imaging Effective for Detecting Surgically Treatable Recurrences in Patients With Melanoma? A Comparative Analysis of Stage-Specific Surveillance Strategies. <i>Annals of Surgery</i> , 2014, 259, 1215-1222.	2.1	46
169	The number and ratio of positive lymph nodes affect pancreatic cancer patient survival after neoadjuvant therapy and pancreaticoduodenectomy. <i>Histopathology</i> , 2016, 68, 210-220.	1.6	46
170	Operative and short-term oncologic outcomes of laparoscopic versus open liver resection for colorectal liver metastases located in the posterosuperior liver: a propensity score matching analysis. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2018, 32, 1776-1786.	1.3	46
171	Physical activity and exercise during preoperative pancreatic cancer treatment. <i>Supportive Care in Cancer</i> , 2019, 27, 2275-2284.	1.0	45
172	Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 253-263.	0.7	44
173	Mapping FACT-Melanoma Quality-of-Life Scores to EQ-5D Health Utility Weights. <i>Value in Health</i> , 2011, 14, 900-906.	0.1	44
174	The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy. <i>Annals of Surgical Oncology</i> , 2015, 22, 1221-1228.	0.7	44
175	Polymorphisms of Nucleotide Excision Repair Genes Predict Melanoma Survival. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1813-1821.	0.3	43
176	Adrenal Metastectomy is Safe in Selected Patients. <i>World Journal of Surgery</i> , 2014, 38, 1336-1342.	0.8	43
177	Melanoma metastatic to cervical lymph nodes: Can radiotherapy replace formal dissection after local excision of nodal disease?. <i>Head and Neck</i> , 2005, 27, 718-721.	0.9	42
178	Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 1975-1985.	0.9	42
179	Identification of a melanoma susceptibility locus and somatic mutation in <i>TET2</i> . <i>Carcinogenesis</i> , 2014, 35, 2097-2101.	1.3	41
180	Surgical Resection of Synchronously Metastatic Adrenocortical Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 146-151.	0.7	41

#	ARTICLE	IF	CITATIONS
181	Risk-stratified clinical pathways decrease the duration of hospitalization and costs of perioperative care after pancreatectomy. <i>Surgery</i> , 2018, 164, 424-431.	1.0	41
182	Joint Effect of Multiple Common SNPs Predicts Melanoma Susceptibility. <i>PLoS ONE</i> , 2013, 8, e85642.	1.1	40
183	Selective Perioperative Administration of Pasireotide is More Cost-Effective Than Routine Administration for Pancreatic Fistula Prophylaxis. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 636-646.	0.9	39
184	Anthropometric Changes in Patients with Pancreatic Cancer Undergoing Preoperative Therapy and Pancreatoduodenectomy. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 703-712.	0.9	39
185	Abdominal Visceral Lesions in von Hippel-Lindau Disease: Incidence and Clinical Behavior of Pancreatic and Adrenal Lesions at a Single Center. <i>World Journal of Surgery</i> , 2006, 30, 665-669.	0.8	38
186	Reoperative pancreaticoduodenectomy for periampullary carcinoma. <i>American Journal of Surgery</i> , 1996, 172, 432-438.	0.9	37
187	Protein Expression of PTTG1 as a Diagnostic Biomarker in Adrenocortical Carcinoma. <i>Annals of Surgical Oncology</i> , 2018, 25, 801-807.	0.7	37
188	Role of Neoadjuvant Therapy in the Multimodality Treatment of Older Patients with Pancreatic Cancer. <i>Journal of the American College of Surgeons</i> , 2014, 219, 111-120.	0.2	36
189	Predicting the risks of venous thromboembolism versus post-pancreatectomy haemorrhage: analysis of 13771 NSQIP patients. <i>Hpb</i> , 2014, 16, 373-383.	0.1	35
190	Borderline Resectable Pancreatic Cancer: What Have We Learned and Where Do We Go From Here?. <i>Annals of Surgical Oncology</i> , 2011, 18, 608-610.	0.7	34
191	Pancreatic intraepithelial neoplasia and histological changes in non-neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma. <i>Histopathology</i> , 2013, 63, 841-851.	1.6	34
192	Robotic-Assisted Retroperitoneoscopic Adrenalectomy: Making a Good Procedure Even Better. <i>American Surgeon</i> , 2013, 79, 84-89.	0.4	34
193	Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 155-163.	0.9	34
194	Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. <i>Annals of Surgery</i> , 2020, 271, 996-1002.	2.1	34
195	Current approaches and future strategies for pancreatic carcinoma. <i>Investigational New Drugs</i> , 2000, 18, 43-56.	1.2	33
196	Outcomes and Economic Analysis of Routine Preoperative 4-Dimensional CT for Surgical Intervention in de novo Primary Hyperparathyroidism: Does Clinical Benefit Justify the Cost?. <i>Journal of the American College of Surgeons</i> , 2012, 214, 629-637.	0.2	32
197	Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer. <i>Physical Biology</i> , 2014, 11, 065002.	0.8	32
198	Incidental Gallbladder Cancer: Residual Cancer Discovered at Oncologic Extended Resection Determines Outcome: A Report from High- and Low-Incidence Countries. <i>Annals of Surgical Oncology</i> , 2017, 24, 2334-2343.	0.7	31

#	ARTICLE	IF	CITATIONS
199	Malignant melanoma: relationship of the human leukocyte antigen Class II gene DQB1*0301 to disease recurrence in American Joint Committee on Cancer Stage I or II. , 1996, 78, 758-763.		30
200	Multimodality Therapy Offers a Chance for Cure in Patients with Pancreatic Adenocarcinoma Deemed Unresectable at First Operative Exploration. Journal of the American College of Surgeons, 2012, 215, 41-51.	0.2	30
201	Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater. Annals of Surgical Oncology, 2017, 24, 2031-2039.	0.7	30
202	A High Positive Lymph Node Ratio is Associated with Distant Recurrence after Surgical Resection of Ampullary Carcinoma. Journal of Gastrointestinal Surgery, 2012, 16, 2056-2063.	0.9	29
203	Mitochondrial DNA Copy Number in Peripheral Blood and Melanoma Risk. PLoS ONE, 2015, 10, e0131649.	1.1	29
204	Significance of Plasma Cytokine Levels in Melanoma Patients With Histologically Negative Sentinel Lymph Nodes. Annals of Surgical Oncology, 2001, 8, 116-122.	0.7	28
205	Conditional Survival Estimates Improve Over 5 Years for Melanoma Survivors with Node-Positive Disease. Annals of Surgical Oncology, 2010, 17, 2015-2023.	0.7	28
206	Genetic Variants in Fanconi Anemia Pathway Genes BRCA2 and FANCA Predict Melanoma Survival. Journal of Investigative Dermatology, 2015, 135, 542-550.	0.3	28
207	Impact of pancreatectomy on long-term patient-reported symptoms and quality of life in recurrence-free survivors of pancreatic and periampullary neoplasms. Journal of Surgical Oncology, 2017, 115, 144-150.	0.8	28
208	Extended Lymphadenectomy Is Required for Incidental Gallbladder Cancer Independent of Cystic Duct Lymph Node Status. Journal of Gastrointestinal Surgery, 2018, 22, 43-51.	0.9	28
209	Genotype-phenotype pancreatic neuroendocrine tumor relationship in multiple endocrine neoplasia type 1 patients: A 23-year experience at a single institution. Surgery, 2018, 163, 212-217.	1.0	28
210	Advances in the diagnosis and treatment of adenocarcinoma of the pancreas. Cancer Treatment and Research, 1997, 90, 109-125.	0.2	28
211	Current Status of Adjuvant Therapy for Pancreatic Cancer. Oncologist, 2010, 15, 1205-1213.	1.9	26
212	Loss of muscle mass during preoperative chemotherapy as a prognosticator for poor survival in patients with colorectal liver metastases. Surgery, 2019, 165, 329-336.	1.0	26
213	Obesity-related genetic variants, human pigmentation, and risk of melanoma. Human Genetics, 2013, 132, 793-801.	1.8	25
214	The role of genetics in the surgical management of familial endocrinopathy syndromes. Journal of the American College of Surgeons, 2003, 197, 818-831.	0.2	24
215	Polymorphisms of the neuronal and inducible nitric oxide synthase genes and the risk of cutaneous melanoma. Cancer, 2007, 109, 1570-1578.	2.0	24
216	Pheochromocytoma. Current Treatment Options in Oncology, 2003, 4, 329-337.	1.3	23

#	ARTICLE	IF	CITATIONS
217	Role of Immune Response, Inflammation, and Tumor Immune Response-Related Cytokines/Chemokines in Melanoma Progression. <i>Journal of Investigative Dermatology</i> , 2019, 139, 2352-2358.e3.	0.3	23
218	Adrenocortical Carcinoma. <i>Surgical Oncology Clinics of North America</i> , 2006, 15, 535-553.	0.6	22
219	Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX. <i>Pancreas</i> , 2019, 48, 837-843.	0.5	22
220	Presence of the human leukocyte antigen class II gene DRB1*1101 predicts interferon γ levels and disease recurrence in melanoma patients. <i>Annals of Surgical Oncology</i> , 2002, 9, 587-593.	0.7	21
221	Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease. <i>Cancer</i> , 2008, 112, 2030-2037.	2.0	21
222	Genetic variants in the PIWI-miRNA pathway gene <i>DCP1A</i> predict melanoma disease-specific survival. <i>International Journal of Cancer</i> , 2016, 139, 2730-2737.	2.3	21
223	Neoadjuvant Chemoradiation for Adenocarcinoma of the Pancreas. <i>Surgical Oncology Clinics of North America</i> , 1998, 7, 183-197.	0.6	20
224	Survival and Quality of Life of Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Interferon-Based Chemoradiation: A Phase II Trial. <i>Annals of Surgical Oncology</i> , 2011, 18, 3615-3622.	0.7	20
225	Functional Variants in Notch Pathway Genes <i>NCOR2</i> , <i>NCSTN</i> , and <i>MAML2</i> Predict Survival of Patients with Cutaneous Melanoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1101-1110.	1.1	20
226	Outpatient virtual clinical encounters after complex surgery for cancer: a prospective pilot study of "TeleDischarge". <i>Journal of Surgical Research</i> , 2016, 202, 196-203.	0.8	20
227	Surgical Management of Thyroid Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2005, 3, 458-466.	2.3	19
228	Genetic variants in the vitamin D pathway genes <i>VDBP</i> and <i>RXRRA</i> modulate cutaneous melanoma disease-specific survival. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 176-185.	1.5	19
229	Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-15.	1.5	19
230	Minimally Invasive Surgery for Primary and Metastatic Adrenal Malignancy. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 309-326.	0.6	19
231	Vein resection during pancreaticoduodenectomy for pancreatic adenocarcinoma: Patency rates and outcomes associated with thrombosis. <i>Journal of Surgical Oncology</i> , 2018, 117, 1648-1654.	0.8	18
232	On the Interplay of Telomeres, Nevi and the Risk of Melanoma. <i>PLoS ONE</i> , 2012, 7, e52466.	1.1	18
233	Gene Variants in Angiogenesis and Lymphangiogenesis and Cutaneous Melanoma Progression. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 827-834.	1.1	17
234	Risk-Stratified Pancreatectomy Clinical Pathway Implementation and Delayed Gastric Emptying. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 2221-2230.	0.9	17

#	ARTICLE	IF	CITATIONS
235	Supports and Barriers to Home-Based Physical Activity During Preoperative Treatment of Pancreatic Cancer: A Mixed-Methods Study. <i>Journal of Physical Activity and Health</i> , 2019, 16, 1113-1122.	1.0	17
236	Integrated pathway and epistasis analysis reveals interactive effect of genetic variants at <i>TERF1</i> and <i>AFAP1L2</i> loci on melanoma risk. <i>International Journal of Cancer</i> , 2015, 137, 1901-1909.	2.3	16
237	Is early-stage pancreatic adenocarcinoma truly early: stage migration on final pathology with surgery-first versus neoadjuvant therapy sequencing. <i>Hpb</i> , 2019, 21, 1203-1210.	0.1	16
238	Functional annotation of melanoma risk loci identifies novel susceptibility genes. <i>Carcinogenesis</i> , 2020, 41, 452-457.	1.3	15
239	Factors Influencing Exercise Following Pancreatic Tumor Resection. <i>Annals of Surgical Oncology</i> , 2021, 28, 2299-2309.	0.7	15
240	The Expression of PTEN Is Associated With Improved Prognosis in Patients With Ampullary Adenocarcinoma After Pancreaticoduodenectomy. <i>Archives of Pathology and Laboratory Medicine</i> , 2013, 137, 1619-1626.	1.2	14
241	The role of preoperative therapy prior to pancreatoduodenectomy for distal cholangiocarcinoma. <i>American Journal of Surgery</i> , 2019, 218, 145-150.	0.9	14
242	Significance of Cancer Cells at the Vein Edge in Patients with Pancreatic Adenocarcinoma Following Pancreatectomy with Vein Resection. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 368-379.	0.9	14
243	Measurement of Portal Vein Blood Circulating Tumor Cells is Safe and May Correlate With Outcomes in Resected Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 4615-4622.	0.7	14
244	Promoter polymorphisms in matrix metalloproteinase 1 and risk of cutaneous melanoma. <i>European Journal of Cancer</i> , 2011, 47, 107-115.	1.3	13
245	Genetic variants in <i>RORA</i> and <i>DNMT1</i> associated with cutaneous melanoma survival. <i>International Journal of Cancer</i> , 2018, 142, 2303-2312.	2.3	13
246	Positive cystic duct margin at index cholecystectomy in incidental gallbladder cancer is an important negative prognosticator. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1061-1068.	0.5	13
247	Expression of Epithelial-Mesenchymal Transition Markers in Treated Pancreatic Ductal Adenocarcinoma. <i>Pancreas</i> , 2019, 48, 1367-1372.	0.5	13
248	Iterative Changes in Risk-Stratified Pancreatectomy Clinical Pathways and Accelerated Discharge After Pancreaticoduodenectomy. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 1054-1062.	0.9	13
249	Potential role for intraoperative gamma probe identification of normal parathyroid glands. <i>American Journal of Surgery</i> , 2003, 186, 711-717.	0.9	12
250	LETTER TO THE EDITOR. <i>Annals of Surgery</i> , 2003, 237, 594-595.	2.1	12
251	Contemporary analysis of complications associated with biliary stents during neoadjuvant therapy for pancreatic adenocarcinoma. <i>Hpb</i> , 2019, 21, 662-668.	0.1	12
252	Operation duration and adrenal gland size, but not BMI, are correlated with complication rate for posterior retroperitoneoscopic adrenalectomy for benign diseases. <i>Surgery</i> , 2019, 165, 637-643.	1.0	12

#	ARTICLE	IF	CITATIONS
253	The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2020, 27, 3939-3947.	0.7	12
254	Factors associated with melanoma incidence and prognosis. , 1996, 12, 379-385.		11
255	Genetic variants in <i>ELOVL2</i> and <i>HSD17B12</i> predict melanoma-specific survival. <i>International Journal of Cancer</i> , 2019, 145, 2619-2628.	2.3	11
256	Association between functional polymorphisms in genes involved in the MAPK signaling pathways and cutaneous melanoma risk. <i>Carcinogenesis</i> , 2013, 34, 885-892.	1.3	10
257	Natural and orthogonal model for estimating gene-gene interactions applied to cutaneous melanoma. <i>Human Genetics</i> , 2014, 133, 559-574.	1.8	10
258	Developing a Value Framework: Utilizing Administrative Data to Assess an Enhanced Care Initiative. <i>Journal of Surgical Research</i> , 2021, 262, 115-120.	0.8	10
259	Pathologic Response to Preoperative Therapy as a Novel Prognosticator for Ampullary and Duodenal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2017, 24, 3954-3963.	0.7	9
260	Circulating Tumor Cells and Transforming Growth Factor Beta in Resected Pancreatic Adenocarcinoma. <i>Journal of Surgical Research</i> , 2019, 243, 90-99.	0.8	9
261	Genetic variants in <i>PDSS1</i> and <i>SLC16A6</i> of the ketone body metabolic pathway predict cutaneous melanoma-specific survival. <i>Molecular Carcinogenesis</i> , 2020, 59, 640-650.	1.3	9
262	A comprehensive genome-wide analysis of melanoma Breslow thickness identifies interaction between <i>CDC42</i> and <i>SCIN</i> genetic variants. <i>International Journal of Cancer</i> , 2016, 139, 2012-2020.	2.3	8
263	4-Nitroquinoline-1-oxide-induced mutagen sensitivity and risk of cutaneous melanoma. <i>Melanoma Research</i> , 2016, 26, 181-187.	0.6	8
264	Genetic variants in the genes encoding rho GTPases and related regulators predict cutaneous melanoma-specific survival. <i>International Journal of Cancer</i> , 2017, 141, 721-730.	2.3	8
265	First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 619-627.	0.7	8
266	Impact of Intraoperative Dexamethasone on Surgical and Oncologic Outcomes for Patients with Resected Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 1563-1569.	0.7	8
267	Evaluation of Plasma IL-6 in Patients with Melanoma as a Prognostic and Checkpoint Immunotherapy Predictive Biomarker. <i>Journal of Investigative Dermatology</i> , 2022, 142, 2046-2049.e3.	0.3	8
268	Association of Common Genetic Polymorphisms with Melanoma Patient IL-12p40 Blood Levels, Risk, and Outcomes. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2266-2272.	0.3	7
269	Novel Genetic Variants of <i>ALG6</i> and <i>GALNTL4</i> of the Glycosylation Pathway Predict Cutaneous Melanoma-Specific Survival. <i>Cancers</i> , 2020, 12, 288.	1.7	7
270	Nodal Recurrence is a Primary Driver of Early Relapse for Patients with Sentinel Lymph Node-Positive Melanoma in the Modern Therapeutic Era. <i>Annals of Surgical Oncology</i> , 2021, 28, 3480-3489.	0.7	7

#	ARTICLE	IF	CITATIONS
271	No prognostic value added by vitamin D pathway SNPs to current prognostic system for melanoma survival. PLoS ONE, 2017, 12, e0174234.	1.1	7
272	Preoperative chemoradiation for adenocarcinoma of the pancreas: M.D. Anderson experience. Journal of Surgical Oncology, 1995, 11, 132-140.	1.4	6
273	Rapid direct determination of HLA-DQB1 $\hat{=}$ 0301 in the whole blood of normal individuals and cancer patients by specific polymerase chain reaction amplification. Journal of Immunological Methods, 1996, 199, 61-68.	0.6	6
274	Variants in <i>melanocortin 1 receptor</i> gene contribute to risk of melanoma – a direct sequencing analysis in a Texas population. Pigment Cell and Melanoma Research, 2013, 26, 422-425.	1.5	6
275	Endocrine incidentalomas. Current Problems in Surgery, 2016, 53, 219-246.	0.6	6
276	Preoperative Chemoradiation for Borderline Resectable Pancreatic Cancer: The New Standard?. Annals of Surgery, 2018, 268, 223-224.	2.1	6
277	Genetic variants in the calcium signaling pathway genes are associated with cutaneous melanoma-specific survival. Carcinogenesis, 2019, 40, 279-288.	1.3	6
278	Association between putative functional variants in the <i>PSMB9</i> gene and risk of melanoma – reanalysis of published melanoma genome-wide association studies. Pigment Cell and Melanoma Research, 2013, 26, 392-401.	1.5	5
279	The relationship between blood <i>IL-12p40</i> level and melanoma progression. International Journal of Cancer, 2015, 136, 1874-1880.	2.3	5
280	Genetic Variants in WNT2B and BTRC Predict Melanoma Survival. Journal of Investigative Dermatology, 2017, 137, 1749-1756.	0.3	5
281	A <i>PGC1β</i> genetic variant associated with nevus count and melanoma mortality. International Journal of Cancer, 2017, 141, 1066-1067.	2.3	5
282	Genetic variants in the metzincin metallopeptidase family genes predict melanoma survival. Molecular Carcinogenesis, 2018, 57, 22-31.	1.3	5
283	Genetic variants in glutamine metabolic pathway genes predict cutaneous melanoma-specific survival. Molecular Carcinogenesis, 2019, 58, 2091-2103.	1.3	5
284	Genetic characterization of medullary thyroid cancer in childhood survivors of the Chernobyl accident. Surgery, 2019, 165, 58-63.	1.0	5
285	Genetic variants in the integrin signaling pathway genes predict cutaneous melanoma survival. International Journal of Cancer, 2017, 140, 1270-1279.	2.3	4
286	Pathological diaphragmatic invasion by colorectal liver metastases is associated with RAS mutation, peritoneal recurrence and worse survival. Hpb, 2018, 20, 57-63.	0.1	4
287	Perioperative blood transfusions for vein resection during pancreaticoduodenectomy for pancreatic adenocarcinoma: Identification of clinical targets for optimization. Hpb, 2019, 21, 841-848.	0.1	4
288	Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma. Pancreatology, 2021, 21, 200-207.	0.5	4

#	ARTICLE	IF	CITATIONS
289	Perioperative blood transfusions and survival in resected pancreatic adenocarcinoma patients given multimodality therapy. <i>Journal of Surgical Oncology</i> , 2021, 124, 1381-1389.	0.8	4
290	Genetic variants of PDGF signaling pathway genes predict cutaneous melanoma survival. <i>Oncotarget</i> , 2017, 8, 74595-74606.	0.8	3
291	Genetic variants in TKT and DERA in the nicotinamide adenine dinucleotide phosphate pathway predict melanoma survival. <i>European Journal of Cancer</i> , 2020, 136, 84-94.	1.3	3
292	Association of genetic variants of TMEM135 and PEX5 in the peroxisome pathway with cutaneous melanoma-specific survival. <i>Annals of Translational Medicine</i> , 2021, 9, 396-396.	0.7	3
293	History of preoperative therapy for pancreatic cancer and the MD Anderson experience. <i>Journal of Surgical Oncology</i> , 2021, 123, 1414-1422.	0.8	3
294	Contemporary Assessment of Need for Palliative Bypass After Aborted Pancreatoduodenectomy Following Neoadjuvant Therapy. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 352-359.	0.9	3
295	Prognostic significance of preoperative and postoperative CA 19â€9 normalization in pancreatic adenocarcinoma treated with neoadjuvant therapy or surgery first. <i>Journal of Surgical Oncology</i> , 2022, 126, 1021-1027.	0.8	3
296	Melanoma Expression Genes Identified through Genome-Wide Association Study of Breslow Tumor Thickness. <i>Journal of Investigative Dermatology</i> , 2017, 137, 253-257.	0.3	2
297	Preoperative (Neoadjuvant) Therapy for Resectable Adenocarcinoma of the Pancreas. , 2002, , 243-254.		2
298	Reply to Z. Li et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 3674-3675.	0.8	1
299	ASO Author Reflections: Temporary Mesocaval Shunt: Indications and Technique for Safe Resection of Pancreatic Tumors With Mesenteric Venous Occlusion. <i>Annals of Surgical Oncology</i> , 2019, 26, 579-580.	0.7	1
300	Genetic variants of SDCCAG8 and MAGI2 in mitosisâ€related pathway genes are independent predictors of cutaneous melanomaâ€specific survival. <i>Cancer Science</i> , 2021, 112, 4355-4364.	1.7	1
301	Standard Forms of Pancreatic Resection. , 1998, , 181-199.		1
302	Surgical Management of Distant Melanoma Metastases. , 2020, , 1359-1402.		1
303	Multiple Endocrine Neoplasia. , 2011, , 29-49.		1
304	AJCC 8th edition pathologic nodal staging of resected pancreatic adenocarcinoma predicts survival regardless of treatment sequencing. <i>Surgical Oncology</i> , 2022, 40, 101673.	0.8	1
305	Resection of the Superior Mesenteric-Portal Vein Confluence During Pancreaticoduodenectomy. , 1997, , 215-225.		0
306	Surgical Management of Distant Melanoma Metastases. , 2019, , 1-44.		0

#	ARTICLE	IF	CITATIONS
307	Novel genetic variants of and of the endosome-related pathway predict cutaneous melanoma-specific survival. American Journal of Cancer Research, 2020, 10, 3382-3394.	1.4	0
308	Genetic variants of and in myeloid cell-related pathway genes independently predict cutaneous melanoma-specific survival. American Journal of Cancer Research, 2021, 11, 3252-3262.	1.4	0